A detailed history of Vanguard Group Inc transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,954,285 shares of VOR stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,954,285
Previous 1,954,285 -0.0%
Holding current value
$1.7 Million
Previous $1.95 Million 30.04%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.0 - $2.2 $141,386 - $311,049
141,386 Added 7.8%
1,954,285 $1.95 Million
Q1 2024

May 10, 2024

BUY
$1.8 - $2.85 $124,984 - $197,892
69,436 Added 3.98%
1,812,899 $4.3 Million
Q4 2023

Feb 14, 2024

BUY
$1.66 - $2.63 $44,848 - $71,054
27,017 Added 1.57%
1,743,463 $3.92 Million
Q3 2023

Nov 14, 2023

BUY
$2.1 - $3.35 $8,326 - $13,282
3,965 Added 0.23%
1,716,446 $3.64 Million
Q2 2023

Aug 14, 2023

BUY
$3.09 - $5.33 $411,535 - $709,865
133,183 Added 8.43%
1,712,481 $5.29 Million
Q1 2023

May 15, 2023

BUY
$4.68 - $6.96 $1.82 Million - $2.7 Million
387,968 Added 32.57%
1,579,298 $8.5 Million
Q4 2022

Feb 10, 2023

BUY
$3.77 - $7.43 $2.01 Million - $3.97 Million
534,188 Added 81.29%
1,191,330 $7.92 Million
Q2 2022

Aug 12, 2022

SELL
$3.89 - $6.44 $12,856 - $21,284
-3,305 Reduced 0.5%
657,142 $3.27 Million
Q1 2022

May 13, 2022

SELL
$6.04 - $12.23 $1.76 Million - $3.57 Million
-291,679 Reduced 30.63%
660,447 $3.99 Million
Q4 2021

Feb 14, 2022

SELL
$11.32 - $18.02 $3.95 Million - $6.29 Million
-348,930 Reduced 26.82%
952,126 $11.1 Million
Q3 2021

Nov 12, 2021

BUY
$12.24 - $20.38 $5.6 Million - $9.33 Million
457,673 Added 54.27%
1,301,056 $20.4 Million
Q2 2021

Aug 13, 2021

BUY
$18.65 - $38.78 $15.7 Million - $32.7 Million
843,383 New
843,383 $15.7 Million

Others Institutions Holding VOR

About Vor Biopharma Inc.


  • Ticker VOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,056,300
  • Market Cap $33.1M
  • Description
  • Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...
More about VOR
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.